Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Looking for a Growth Stock? 3 Reasons Why Masimo (MASI) is a Solid Choice
by Zacks Equity Research
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
Masimo (MASI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Masimo (MASI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments drive its Q1 sales.
Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 1.09% and 3.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Masimo's (MASI) Sound United Buyout to Boost Product Portfolio
by Zacks Equity Research
Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View
by Zacks Equity Research
Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Announces Favorable Study Results on SpHb
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.
Venus Concept (VERO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
Why Is Masimo (MASI) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
Masimo's (MASI) SedLine Receives FDA's Pediatric Indication
by Zacks Equity Research
The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
Masimo (MASI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 10% and 2.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo (MASI) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.